Metabolic control analysis in drug discovery and disease

被引:201
作者
Cascante, M
Boros, LG
Comin-Anduix, B
de Atauri, P
Centelles, JJ
Lee, PWN
机构
[1] Univ Barcelona, IDIBAPS, CeRQT, PCB,Dept Biochem & Mol Biol, E-08028 Barcelona, Catalonia, Spain
[2] Univ Calif Los Angeles, Sch Med, Harbor UCLA Res & Educ Inst, Torrance, CA 90502 USA
关键词
D O I
10.1038/nbt0302-243
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Metabolic control analysis (MCA) provides a quantitative description of substrate flux in response to changes in system parameters of complex enzyme systems. Medical applications of the approach include the following: understanding the threshold effect in the manifestation of metabolic diseases; investigating the gene dose effect of aneuploidy in inducing phenotypic transformation in cancer; correlating the contributions of individual genes and phenotypic characteristics in metabolic disease (e. g., diabetes); identifying candidate enzymes in pathways suitable as targets for cancer therapy; and elucidating the function of "silent" genes by identifying metabolic features shared with genes of known pathways. MCA complements current studies of genomics and proteomics, providing a link between biochemistry and functional genomics that relates the expression of genes and gene products to cellular biochemical and physiological events. Thus, it is an important tool for the study of genotype-phenotype correlations. It allows genes to be ranked according to their importance in controlling and regulating cellular metabolic networks. We can expect that MCA will have an increasing impact on the choice of targets for intervention in drug discovery.
引用
收藏
页码:243 / 249
页数:7
相关论文
共 71 条
[41]   What do mitochondrial diseases teach us about normal mitochondrial functions... that we already knew: threshold expression of mitochondrial defects [J].
Mazat, JP ;
Rossignol, R ;
Malgat, M ;
Rocher, C ;
Faustin, B ;
Letellier, T .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS, 2001, 1504 (01) :20-30
[43]   A breakpoint map of recurrent chromosomal rearrangements in human neoplasia [J].
Mitelman, F ;
Mertens, F ;
Johansson, B .
NATURE GENETICS, 1997, 15 (Suppl 4) :417-474
[44]  
MITELMAN F, 1994, CATALOGUE CHROMOSOME
[45]  
Nielsen J, 1998, BIOTECHNOL BIOENG, V58, P125, DOI 10.1002/(SICI)1097-0290(19980420)58:2/3<125::AID-BIT3>3.0.CO
[46]  
2-N
[47]   From DNA sequence to biological function [J].
Oliver, SG .
NATURE, 1996, 379 (6566) :597-600
[48]   Triosephosphate isomerase deficiency: Predictions and facts [J].
Orosz, F ;
Vertessy, BG ;
Hollan, S ;
Horanyi, M ;
Ovadi, J .
JOURNAL OF THEORETICAL BIOLOGY, 1996, 182 (03) :437-447
[49]   A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations [J].
Raamsdonk, LM ;
Teusink, B ;
Broadhurst, D ;
Zhang, NS ;
Hayes, A ;
Walsh, MC ;
Berden, JA ;
Brindle, KM ;
Kell, DB ;
Rowland, JJ ;
Westerhoff, HV ;
van Dam, K ;
Oliver, SG .
NATURE BIOTECHNOLOGY, 2001, 19 (01) :45-50
[50]   Oxythiamine and dehydroepiandrosterone induce a G1 phase cycle arrest in Ehrlich's tumor cells through inhibition of the pentose cycle [J].
Raïs, B ;
Comin, B ;
Puigjaner, J ;
Brandes, JL ;
Creppy, E ;
Saboureau, D ;
Ennamany, R ;
Lee, WNP ;
Boros, LG ;
Cascante, M .
FEBS LETTERS, 1999, 456 (01) :113-118